New drug may help lung damage after stem cell transplants
NCT ID NCT02669251
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new oral drug called alvelestat (MPH966) in adults who have lung damage (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block an enzyme that may cause lung injury. The trial has two parts: first to find the safest and most effective dose, then to see if that dose improves lung function over up to 12 months. Only 14 participants are enrolled, so results are very early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alvelestat (MPH966)
What this could lead to
If it works, this could point toward a treatment to slow or improve lung damage in people with bronchiolitis obliterans syndrome after a stem cell transplant.
What could go wrong
This is an early, small trial with only 14 participants, so results may not apply to everyone. The drug may not improve lung function or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States